Boston Scientific Corporation (BSX) Stock Analysis

Boston Scientific is a global minimally invasive medical-device company serving hospitals, outpatient clinics, and ambulatory surgery centers through Cardiovascular and MedSurg segments. Its consumables-led model is tied to procedure volumes and avoids dependence on capital equipment cycles. FY2025 revenue reached $20.074 billion, with the United States contributing $12.864 billion, or 64.1%, and Cardiovascular contributing $13.250 billion. Q2 2026 remained operationally strong before the cybersecurity event: sales were $5.442 billion, organic growth was 7.0%, adjusted EPS was $0.86, adjusted operating margin was 28.4%, and free cash flow was $1.290 billion. **The investment case is now defined by a sharp valuation reset:** the stock trades near $43.00 versus a historical FY2025 trailing P/E of 48.8x and P/S of 7.0x, compared with approximately 17x–19x and 3.0x today. Near-term conditions are difficult because the August 25 cyberattack forced withdrawal of 2026 guidance, while PFA competition and WATCHMAN bundling pressure persist. **The principal catalysts are Penumbra’s $14.5 billion acquisition, approximately $1.4 billion of expected revenue, and $500 million of restructuring savings by exiting 2029.**